Issue link: https://www.e-digitaleditions.com/i/1527415
Inhalation OctOber 2024 31 Sustainable innovation in drug delivery Bespak® offers a fully integrated service for the design, development and manufacture of inhaled and nasal drug-device combination products. With proven product development capabilities spanning formu- lation development through scale-up, Bespak also specializes in contract manufacturing to support cus- tomers from concept to commercialization. With established and growing capacity for manufacturing pressurized metered dose inhalers (pMDIs) using low global warming potential propellants, we are support- ing the industry's transition to a sustainable future. In addition, our capabilities include supply of dry pow- der inhaler devices, unit-dose and multi-dose nasal sprays, and via our joint venture Resyca®, soft mist inhalers and soft nasal sprays. Bespak UK: +44 1477 537112 hello@bespak.com www.bespak.com Stability and analytical testing partners Stability testing is a specialist field. If a company does not have in-house experts for method development and validation, outsourcing may be a good solution. is gives manufacturers access to subject matter experts, such as analytical chemists and toxicologists, who can help complete test data analysis, understand deviations and troubleshoot problems. If your test- ing partner is an expert in extractables and leachables (E&L), parallel studies can streamline the route-to- market. Broughton has been conducting stability studies for pharmaceutical manufacturers since 2006, offering its testing and regulatory expertise at every stage of the process. Broughton Group UK: +44 1756 700255 contact@broughton-group.com www.broughton-group.com Role of excipients for respiratory delivery Building upon more than 20 years of experience, Lonza continues to drive research in formulation for inhaled delivery of biologics. Excipient choice in drug formulation plays a key role in this process, and when combining a large molecule with one or more excip- ients, factors such as their own properties, route of administration, dosage form and processing condi- tions need to be considered. With dedicated technol- ogies and facilities, Lonza's scientists are identifying new, leading approaches with excipients and provid- ing support for navigating the regulatory landscape. Lonza Small Molecules US +1 813 286-0404 small.molecules@lonza.com www.lonza.com